PT  - JOURNAL ARTICLE
AU  - Gonzalez, John M.
AU  - Santos-Barbosa, Juan Carlos
AU  - Jaller, Catherine
AU  - Otalora, German
AU  - Hernandez, Luis J.
AU  - Guevara-Suarez, Marcela
AU  - Restrepo, Silvia
TI  - Seroreactivity to SARS-CoV-2 in individuals attending a university campus in Bogotá Colombia
AID  - 10.1101/2021.03.15.21253609
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.15.21253609
4099  - http://medrxiv.org/content/early/2021/12/15/2021.03.15.21253609.short
4100  - http://medrxiv.org/content/early/2021/12/15/2021.03.15.21253609.full
AB  - Most community-specific serological surveys for SARS-CoV-2 antibodies have been performed in healthcare workers and institutions. In this study, IgG antibodies specific to the virus were evaluated in individuals working at a university campus in Bogotá, Colombia. The aim of this work was to determine previous exposure to SARS-CoV-2 in those attending the campus during city lockdown. A total of 237 individuals, including 93 women and 144 men were evaluated using chemiluminescent detection of IgG anti N-viral protein between November and December 2020. There were 32 positives individuals corresponding to a seroprevalence of 13.5% (10 women and 22 men) and mostly asymptomatic (68.75%) and three cluster of seropositive individuals were identified. Only 13 of the seropositive individuals had previous positive detection of SARS-CoV-2 RNA by RT-qPCR performed in average 91 days before serological test. Seropositive individuals did not come from boroughs having higher percentages of SARS-CoV-2 cases in the city. This survey was carried out after the first peak of SARS-CoV-2 transmission in the city, and before the preparedness to reopening the campus for students in 2021, demonstrating a low seroprevalence in high percentage of asymptomatic. These results will help to evaluate some of the strategies stablished to control virus spread in the campus or other similar communities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPartially funding by COVIDA program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocol and informed consent were approved by Ethical Committee of Universidad de Los Andes (Act No 1192-2020)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData does not show in the paper will be available after request